



FOR IMMEDIATE RELEASE

Change in Director Interest

Sydney, Australia 25th June 2012 - NuSep (ASX: NSP) wishes to advise the market that Mr Andrew Goodall, a non-executive Director of NuSep has increased his holding in NuSep by 1,680,000 ordinary shares. The transaction was an off market transfer undertaken for estate planning reasons.

Enclosed is the appendix 3Y.

****ENDS****

For more information please contact:

Swapna Keskar
Company Secretary
+61 2 8415 7300
swapna.keskar@nusep.com





About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteolQ software enabling NuSep to offer a total Proteomics solution from **Fraction to Function**. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
-  **Proteomics Software** – NuSep offers the unique ProteolQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

NuSep Holdings Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 8415 7300
Facsimile +61 2 8415 7399

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PrIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PrIME Biologics process is based on the **P**reparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause 'Mad Cow Disease'. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many countries.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity NUSEP HOLDINGS LIMITED
ABN 33 120 047 556

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Goodall
Date of last notice	16 March 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
Date of change	19 June 2012
No. of securities held prior to change	Direct 17,320,000 ordinary fully paid shares 31,582 35 cent options
Class	Ordinary Shares
Number acquired	1,680,000
Number disposed	NIL
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$47,040
No. of securities held after change	Direct 19,000,000 ordinary fully paid shares 31,582 35 cent options
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-market purchase

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.